[b]I hate to advocate drugs, alcohol, violence, or insanity to anyone, but they've always worked for me.[/b]
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
When someone is called old buddy by another and that someone was not able to attend the SHM for reasons that still baffle
the mind it does kind of make one wonder eh? Never knew they ever checked out who held shares at SHMs. Its more like they knew who you were and do not like you for a reason.
j
And the share price at this time last year 2005 was about $0.39/share. CYGX had no synDNA in June 2004 that we knew of
right? synDNA came out in 2005.
I will pull an Arny. That was then this is now and your point?
JJM
Tatonkano I hope there was no pun intended.
"go to Tools"
RWBs have been called worse.
RBWTs
j
downregul8 I think you will see synDNA sooner than a ssDNA IND. Right now it does look as though of the two technologies
synDNA will give the ROI much sooner.
ssDNA still has delivery problems according to some here yet others say those problems have been solved in part due to synDNA. Unless one can get up close and personal with mangement or those in the "back office R&D" and ask those questions face to face we will never really know what the full story is on ssDNA as it stands today. Next SHM I will be there or bust!
As always enjoy your posts. Kanc does a great job too. bigworld
G and Holyone also. Arny on occasion but rarely.
jjm
nearly if one owns so many shares of a said stock then one would think this person(s) would attend a SHM or two.
Another point if one is worried about his/her large position
in said stock to the point of a penny here or there they may
do better seeking other types of more stable/secure investments. Greed will not buy you happiness nor will it afford you good health.
If one is over their head in said investment then perhaps they would do well to find a price strike it and leave the rest of us to lose our fortunes on our own.
JJM
G now that was a good one!!! (still laughing)
J
I suspect that Eric Estrada is selling real estate to prospective bio tech companies as we speak. Same with
Chuck Woolary.
Florida: come to the hurricane state.
They would be better off moving operations to central New Jersey.
FLA not on your life.
JJM
G and thatmr IF CYGX were a "sham" why have we had so many
scientists involved in R&D from UTMB to the U of Penn Medical
research lab?
And G you are correct about GE and Aldevron. Aldevron I know
has talked about the merits of Cytogenix synDNA technology.
As far as GE goes it does not take a rocket scientist to put assumptions aside when GE has partnered for "reagents". By "reagents" I am not talking chemical solvents either. I am taking bio reagents.
thatmr is right on the penny with the notion that IF CYGX CAN HOLD UP TO ALL OF OUR NEGATIVE QUESTIONS, THEN WITHOUT A DOUBT, WE ARE IN THE RIGHT PLACE.
So far CYGX has held up very well. Arnys questions seem to get the boot just about every single time. Thank you for asking those questions Arny. Without you we might still have doubts.
(big smile)
Jimmy Joe Meeker LTD
Just one more reason to ditch this venture as an investment.
As for me I will take my chances and stay put.
j
Koby sometimes they try to gain trust in order to diguise. Now I am not saying with 100%
certainty that Arny is a basher. Just never has anything positive to say. Ever. And about management forgetaboutit!
Somebody done somebody wrong song.
Things are progressing slowly as expected. It never happens
quickly in biotech or pharma. Those that do happen quickly often rise to the top only to plunge off a cliff. I really do not expect much even after Labor Day.
Just going to wait it out for the month of August and accumulate when and if I can.
I do eventually expect a series of PRs with more than just fluffernutter. Just not for a while.
If thatmr is correct in his analysis it will all happen in due time.
Mr. Kibbles is tired. He is old. Nap time.
JJM
Britannia rules the ocean waves.
Jimmy Joe
Dr. Cy A. Stein, Professor of Medicine at Albert Einstein College of Medicine and Montefiore Medical Center is also on the scientific advisory board of Genta.
Genta and Cytogenix have a few things in common.
Suggestion to check out Genta and their relationship to ongoing cancer research both RNAi and DNA.
Possible customer this Genta?
j
CytoGenix Files US Patent Application for Cancer Treatment
Thursday August 24, 9:45 am ET
HOUSTON--(BUSINESS WIRE)--Aug. 24, 2006--CytoGenix, Inc. (OTCBB:CYGX - News) announced today that it has filed a patent application entitled "Single Stranded Expression Systems for Cancer Genetics and Other Applications" with the US Patent and Trademark Office.
ADVERTISEMENT
The patent application is based on the results of recent experiments published in the journal Clinical Cancer Research by the inventors, CytoGenix' Chief Scientific Officer, Dr. Yin Chen and CytoGenix director and scientific advisor, Dr. Cy A. Stein, Professor of Medicine at Albert Einstein College of Medicine and Montefiore Medical Center. These experiments show that the company's proprietary ssDNA technology effectively combats some types of tumor growth and can be used to silence cancer genes.
Dr. Malcolm Skolnick, CytoGenix, Inc. CEO commented, "This is another example of the robust regulatory activity of CytoGenix' ssDNA expression technology. This patent application seeks protection for use of this technology in cancer treatment, in parallel with our patent applications filed for use of the ssDNA technology in antiviral, anti-inflammatory and antibacterial applications."
Biacore instumentation seems to be quite useful in China.
Lots of articals dealing with Biacore sensors and reseach conducted in China. Interesting indeed.
One such artical
Analysis of hepatitis E virus neutralization sites using monoclonal antibodies directed against a virus capsid protein.
Zhang J, Gu Y, Ge SX, Li SW, He ZQ, Huang GY, Zhuang H, Ng MH, Xia NS.
The Key Laboratory of the Ministry of Education for Cell Biology and Tumor Cell Engineering, School of Life Sciences, Xiamen University, Xiamen 361005, China.
The dimeric form of the recombinant peptide (E2), comprising amino acid 394-606 of the capsid protein of hepatitis E virus (HEV), is strongly recognized by HEV reactive human serum, and when used as a vaccine, it protects rhesus monkeys against experimental HEV infection. In this work.......
Kinetic studies using BIAcore biosensor suggest that the epitope to which 8H3 is directed is partially masked, and thus has limited access by the native antibody.
.........The parallel cross-reaction patterns that these antibodies exhibit against the peptide and the virus, respectively, implicate two interacting conformationally dependent neutralization sites on the HEV particle. These sites might cooperate in the adsorption and penetration of the HEV virus.
Arny only points to the negative downward moves in stock price BigB.
My two parter turned into a one parter. Let us see if I can rectify that situation.
JJM
Slobodan Paessler, D.V.M.
From the University of Texas Medical Branch the Sealy Center for Vaccine Development homepage:
My research has focused on viral pathogenesis and vaccine/diagnostics/antivirals development.
My laboratory works currently on following NIH-funded projects:
1. VEE pathogenesis and vaccine development
Venezuelan equine encephalitis virus (VEEV) produces a “flu-like” human illness and encephalitic signs and symptoms, with mortality rates approaching 1%. The goals of this project are to 1) develop safe and effective VEEV vaccines using chimeric SINV/VEEV viruses that are efficiently produced at large scale, and; 2) study VEEV pathogenesis using reciprocal SINV/VEEV chimeras to assess the roles of structural vs. nonstructural proteins in tissue tropism and pathogenicity.
2. Chimeric Alphaviruses for Serological VEEV Diagnostics
Rapid and accurate diagnosis of a terrorist-initiated or natural VEE outbreak is essential to instituting appropriate control measures to limit the scope of human and equine disease. We are creating chimeric Sindbis/VEE viruses for diagnostic assays and production of immune sera to overcome the shortage of diagnostic capacity. These chimeric viruses would:
1. Improve safety in diagnostic laboratories
2. Eliminate the need for large-scale VEEV production
3. Make VEEV serological diagnostic reagents available to local public health and private diagnostic laboratories to be used safely in a BSL-2 containment
4. Enable laboratories to safely produce high quality, VEEV-specific immune sera under BSL-2 containment using a single inoculum
5. Improve the ability to ship diagnostic tools within and outside of the U.S. (a U.S. Commerce Dept. export permit is required for VEEV)
3. Development of antivirals against VEEV
The development of traditional antiviral drugs requires an extensive screening process and usually only applies to a single specific agent. Therefore there is a great need for the development of a platform technology that can be used to treat diseases caused by emerging viral infections. Recently developed chemically synthesized phosphorodiamidate morpholino oligos (PMO) have many advantages over traditional antisense oligomers and function by steric blockage. In addition PMOs are well tolerated by both humans and animals. We aim to 1) to confirm the inhibitory effects of VEEV-specific PMOs against a variety of VEEV strains in tissue culture, and 2) to determine the in vivo efficacy and therapeutic window of the PMOs in a VEEV mouse model.
4. Vaccine development against Rift Valley fever virus (Dr. Ilya Frolov is a PI on this project)
The RVFV is continuously circulating in livestock-raising regions of Africa. RVFV can be transmitted by many different species of mosquitoes, and thus is a threat wherever large mosquito populations exist in proximity to sheep and cattle farms. Moreover, RVFV is also a significant human pathogen; it causes a self-limited febrile disease in most infected humans with an approximately 1% mortality. The main goal of our research plan is to create a vaccine that will efficiently protect livestock and humans against the disease caused by RVFV. The vaccine testing is performed by my group in our new BSL-4 laboratory (Robert Shope Laboratory) in a murine model.
5. Antivirals against hemorrhagic fever viruses
The objective of this Arenavirus Challenge Grant program is to advance the NWAV-specific antiviral lead (ST-294) through pre-clinical studies, animal efficacy and IND-enabling toxicology, in order to submit a pre-IND application and have drug material ready for human safety studies.
6. Neuroinflammatory response-mediated VEEV clearance from the brain (in development)
Interesting eh? So many viruses to pursue. VEEV is another
in what looks like a long line.
J
Johnny I am simply stating the facts. There is no "fight " with Arny. His/her their agenda is quite obvious. At least for me it is. You may keep your blinders on. I am not here to make friends Johnny. I am here to squelch the negative spin.
Those Karl Rove tactics are clever I have to admit.
Now on with part two of my exciting DD. By the by I would like to thank thatmr once again for inspiring me to do so
since nobody else is.
JJM
GE Healthcare never heard of Cytogenix. Biacore will be GE
Healthcare soon enough. Find out where Biacore is located
Arny. Me think it is possible that Biacore already has heard of Cytogenix.
j
Arny maybe you should sell. The price of a buyout would only be a few bucks. That is according to Pauls logic.
Oh try to come up with some good spin for my previous post.
Looking forward to it slick basher that you are.
JJM
"What would the company be buying anyway? 2 patents and a popcorn machine that makes gelatin?"
This popcorn machine as you put it is going to put CYGX on the map so to speak. Jello dont wiggle like that. Just waiting for some verification aka validation. If it is as good as I have been told it is GE had better bone up.
What we need here is just more patience and a bit more TIME.
jjm
"I posted PR's about companies that make DNA vaccines, and companies that have new CEO's."
Using DNA made the fermented way Arny. Potential CYGX customers Arny. As for the new CEOs of those companies you posted are eventually buying CYGX synDNA because it is much more effective what is your point? OR if they choose they can left behind with their present vaccine using old tech DNA.
CYGX does not want stockholders to think they only have one machine Arny slick basher that you are. You do. You claim they have no backup. Put doubt into everyones mind with the what if scenario. Like what if it breaks down?
What was it you claimed before Cyto got the prototype machine?
That the machine did not work?
What was it you said about Cytos synDNA? That its synDNA did not work.
What was it you claimed about synDNA orders? There were none? When in fact there have been orders and a great deal of interest in synDNA made the Cyto way.
Why is that Arny? Why do you stretch Arny? Getting nervous?
Who do you work for Arny? Tell us all who you work for.
I would really like to email you but you know by now that I will not be doing that anytime during this life.
Keep up the SPIN Arny. I like the way you contort things. Any relation to Karl Rove?
j
As for Aldevron my thoughts are that of Aldevron being in a middleman position where Aldevron gets the benefit of working
with Cyto synDNA for their own biodefense/vaccine research (a perk) while also selling synDNA to other customers outside the loop at a premium where Aldevron would get a handsome take of the sales pie. Of course Cyto would also get a large percent of the sales pie too. After all synDNA is Cytos baby.
Now who is far fetched thatmr? You still think you are off the deep end? Could it be I am in deeper ends than you?
I think I could very well be.
Time for a blood meal. Sun will be up before ya know it.
JJM
Here is some due dilly for ya Arny. I think thatmr is onto sumpting.
GE Buys Biacore for $390M
Healthcare unit acquires Swedish drug development equipment maker as Pfizer divests holdings.
June 20, 2006
GE Healthcare acquired Biacore for $390 million on Tuesday to bring the Swedish company’s technology for protein research to the General Electric subsidiary.
GE is paying SEK 330 ($45) per share for the Uppsala, Sweden-based company. The Biacore board already approved the deal. A tender offer is expected to begin July 10.
GE wants to expand its array of products for doing life sciences research, and Biacore’s protein interaction analysis systems are being used by scientists in the academic, pharmaceutical, biotech, and diagnostics markets.
The machines provide data on the interactions between proteins and other molecules, including drug candidates. The systems are also used by food producers to determine food quality and safety.
“Life sciences is a key area of growth for GE Healthcare, and Biacore is highly complementary and synergistic with our existing protein sciences business,” GE Healthcare CEO Joe Hogan said in a statement.
GE Healthcare Life Sciences CEO Peter Ehrenheim characterized Biacore as one of the fastest-growing life sciences companies. He plans to grow the company even faster by investing in new technologies and tools aimed at researchers in the pharmaceutical industry and academia.
GE shares fell a penny to $33.71 in recent trading, while Biacore shares rose SEK 45 ($6.13) to SEK 327 ($44.52).
Deal Gets a Thumbs Up
Biacore Chairman Donald Parfet said his company had evaluated the offer and received a favorable opinion from Carnegie Investment Bank. UBS Securities advised GE on the transaction.
The deal is still subject to shareholder and regulatory approval and is expected to close in the third quarter. Among the parties that had to agree to the deal was Pfizer, which holds 41 percent of the shares in Biacore.
Zeibrant Lindqvist, managing director of Pfizer Health, said his company was “irrevocably committed to accept the offer.” Pfizer wants to divest its Biacore holdings to focus on its pharmaceutical business.
The GE deal, though, is contingent on a minimum acceptance condition of 90 percent of shares. Management and the Biacore board of directors hold 0.3 percent of the shares and have agreed to the deal.
“As a result of today’s transaction, Biacore will be able to benefit from the additional technical and commercial resources of GE Healthcare to accelerate its growth and further expand our opportunities in protein research,” said Biacore CEO Erik Walldén.
Looks like GE made a wise buy with Biacore.
Not too shabby.
Turn around for screening purposes can be very quick.
For biodefense purposes this can be a very valuable asset. Time is everything. The less time it takes to produce an effective and safe solution the better.
Thanks thatmr.
J
How does this come into play with Cytogenix synDNA and vaccines?
Screening potential. How is that?
Define the characteristics of a protein interaction
Elucidate disease mechanisms, decide on potential drug targets and diagnostic markers
"Over 4000 peer-reviewed scientific publications have used Biacore systems to study protein interactions"
Native and recombinant proteins are used extensively from investigations of disease pathways through to the identification of protein targets for potential drug therapies.
Proteins from normal and diseased tissues can be compared and, using recombinant technology, variations of the proteins of interest can be produced as part of the effort to understand their functionality or to deduce the structure of potential drug candidates.
No other solution provides so much information from a single instrument - specificity, kinetics, affinity, and thermodynamic measurements.
Thermodynamic measurements
For those interested in the in-depth study of binding mechanisms and the role of non-covalent forces involved in complex formation, Biacore T100 is well suited for investigating the thermodynamics of an interaction. Excellent temperature control and buffer degassing facilitate accurate, detailed characterization of transition state formation during association and dissociation phases
Biacore in proteomics
For scientists taking the ‘proteomics approach’ to studying disease pathways and identifying potential drug targets Biacore 3000, with its ability to isolate and characterize proteins that can be recovered under ideal conditions and deposited direct to MALDI target for analysis by mass spectrometry, is a great advantage particularly since they often work with very small amounts of unknown proteins.
Protein interaction array systems facilitate applications in proteomics by providing multiplexed protein interaction analysis of larger numbers of proteins. Biacore A100 offers multiplexed analyses using many samples and multiple immobilized interactants for high information content database construction. Flexchip profiles the interaction of a single sample with hundreds of proteins simultaneously.
Which system should I use?
Good
Better
Best
Biacore's product line.
Biacore A100
Unmatched productivity for protein interaction analysis
Biacore T100
Unmatched performance for protein interaction analysis – from research through to QC
Biacore 3000
Interaction analysis in functional proteomics
- the best choice for sample recovery interfaced with MS
Flexchip
Simultaneous profiling of up to 400 protein interactions
Biacore X
Recover and characterize binding partners
- High quality, single sample interaction analysis within minutes
What does Biacore do and where does it fit in a synDNA scheme?
Well let us see.
Protein interaction analysis in REAL TIME.
Biacore systems define the characteristics of proteins in terms of their specificity of interaction with other molecules, the rates at which they interact (binding and dissociation), and their affinity (how tightly they bind to another molecule).
The systems also provide sensitive, accurate concentration measurements. This is based on the ability of the biomolecule of interest to interact with a specific binding partner, and may therefore be more informative than generic measurement techniques (total protein concentration for example).
No other techniques can provide such comprehensive information in real time, without the use of labels and in one system.
Here is some due dilly for ya Arny. I think thatmr is onto sumpting.
GE Buys Biacore for $390M
Healthcare unit acquires Swedish drug development equipment maker as Pfizer divests holdings.
June 20, 2006
GE Healthcare acquired Biacore for $390 million on Tuesday to bring the Swedish company’s technology for protein research to the General Electric subsidiary.
GE is paying SEK 330 ($45) per share for the Uppsala, Sweden-based company. The Biacore board already approved the deal. A tender offer is expected to begin July 10.
GE wants to expand its array of products for doing life sciences research, and Biacore’s protein interaction analysis systems are being used by scientists in the academic, pharmaceutical, biotech, and diagnostics markets.
The machines provide data on the interactions between proteins and other molecules, including drug candidates. The systems are also used by food producers to determine food quality and safety.
“Life sciences is a key area of growth for GE Healthcare, and Biacore is highly complementary and synergistic with our existing protein sciences business,” GE Healthcare CEO Joe Hogan said in a statement.
- ADVERTISEMENT -
GE Healthcare Life Sciences CEO Peter Ehrenheim characterized Biacore as one of the fastest-growing life sciences companies. He plans to grow the company even faster by investing in new technologies and tools aimed at researchers in the pharmaceutical industry and academia.
GE shares fell a penny to $33.71 in recent trading, while Biacore shares rose SEK 45 ($6.13) to SEK 327 ($44.52).
Deal Gets a Thumbs Up
Biacore Chairman Donald Parfet said his company had evaluated the offer and received a favorable opinion from Carnegie Investment Bank. UBS Securities advised GE on the transaction.
The deal is still subject to shareholder and regulatory approval and is expected to close in the third quarter. Among the parties that had to agree to the deal was Pfizer, which holds 41 percent of the shares in Biacore.
Zeibrant Lindqvist, managing director of Pfizer Health, said his company was “irrevocably committed to accept the offer.” Pfizer wants to divest its Biacore holdings to focus on its pharmaceutical business.
The GE deal, though, is contingent on a minimum acceptance condition of 90 percent of shares. Management and the Biacore board of directors hold 0.3 percent of the shares and have agreed to the deal.
“As a result of today’s transaction, Biacore will be able to benefit from the additional technical and commercial resources of GE Healthcare to accelerate its growth and further expand our opportunities in protein research,” said Biacore CEO Erik Walldén.
Arny how about some due dilligence?
I like how you post meaningless stuff about what other companies are trying to do. Meanwhile you are missing the picture presented to you.
Here are some morsels to munch a bunch on in the next few posts.
Now try to restrain yourself from a negative spin.
PS Arny-> CYGX announced the prototype machine made by Alfa.
They tested it and by all accounts it worked fine. Cyto put their PR out about the prototype right?
Psssst! I want to tell you a secret. Come closer. Thats it.
Companies do not put PRs out about every piece of equipment
they purchase. CYGX may already have more than a few synDNA
devices at their disposal. The backup may already be there
Arny. Make you nervous? And Cytogenix did not even put a PR out that they had a spare or two. Most companies do not bother to. Common practice.
Do not call Alfa Laval. They will not say. Maybe
LW or Kurt Berens can answer your question. Better get Ilene to do the deed. Like G posted they know your voice.
X O X
Jimmy (great big smile)
thatmr I have some DD for you.
Malcolm's favorite ice cream is vanilla.
Strawberry is a close second.
jjm ltd
As I recall Aldevron already has compliant facilities capable of synDNA manufacture.
Okay ask away.
Jimmy Joe
How do you know "we" have just one machine?
JJM
Arny did it ever occur to you that they need no full blown
advertising. They already have THE key companies involved. What more do they need? It may be other companies trying to play Ketchup soon (biotech time lines).
thatmr dropped you clues as to why. They will have all the business they can handle shortly (which in biotech time means a year or two). There may also be an explaination as to why they have not broken ground on the new facility. Would they have bothered hiring Dr Ma if they did not intend to manufacture or oversee the manufacture of synDNA? Would they have hired Alfa Laval if they had no intention of building
sometime in the future? Could it be someone else will be
providing temporary facilities that are already compliant until it is cost effective for Cytogenix to do it themselves?
I dunno
jj
Arny that is the one!
In my post I never said anything about Aldevron making synDNA.
I asked where the CONTACT information was.
Aldevron now has a "contact Cytogenix for further information"
at the end of each PR.
Maybe Micheal Chambers was a temporary thing until Cytogenix
was able to handle incoming calls better?
J
"Pitiful performance, by any standard."
Whatever you say bigworld. Whatever you say.
Fact that this company's performance is NORMAL.
Difference between dispensing drugs versus actually working
in an R&D facility. Get it straight.
J
You know that Aldevron had themselves down as a contact
when that PR first came out Arny.
You are ONE(two) slick basher(s).
Just bail out and quit your complaining and whining.
I hope the share price goes to $0.50s.
Your agenda is clear to me and others.
Have not received an email from me lately?
Let us put it this way "Arny" I have not shared all I know with you. Never will. Time for you to do some DD yet again.
There is something you are missing and I love it.
Meantime my suggestion stands. Dump out and save yourself
and others aggrevation. This investment is NOT for impatient people like you. It is just that simple.
Keep your eye on LBIX Arny. That one is also down. Maybe trouble with that one too? HA!
Keep whining.
jj
true true Neo. CYGX is a long way away from CFP. What is the current burn rate per Q?
Good point Neo. ThatMister if everything is as you say it is
where does Aldevron fit in? GE did not just cut them out did they?
Is Aldevron tied to the hip with Maxygen? Is GE also in collaboration with these two companies?
Give us more Monk.
TIA
Intrigued
JJ
After going to Yahoo! I decided to go to Aldevron.
They now just have a contact CYGX at their homepage.
I guess this proves Arny is onto something. Time to dump out
Arny?
I know what I read when the PR first came out.
Maybe CYGX decided to handle the contact stuff.
You decide.
J
Arny YES I DID SAY!
If you would go to Yahoo PRs you will see that the PR I am referring to has been removed. How convenient for you.
If you had been paying attention to my posts which you do not
you and your "significant other" would have noticed Micheal Chambers and Aldevron as contacts under the Yahoo version
of THIS PR:
From Cytogenix homepage:
CytoGenix Receives First Order for synDNA™
Houston, TX (March 30, 2006) - CytoGenix, Inc. (CYGX.OB) announced receiving its first purchase order for synDNA™ synthetic DNA. The order was placed by Aldevron (Fargo, North Dakota), a leading worldwide supplier of DNA for research and clinical applications. CytoGenix and Aldevron have joined forces to meet the special needs of the market for multi-gram quantities of highly pure DNA.
"The CytoGenix synDNA™ technology allows us to offer a broader range of solutions to gene therapy and DNA vaccine researchers" said Dr. Michael Chambers, President and CEO of Aldevron. "One of our goals is to help expand the field of DNA-based pharmaceuticals. We welcome the relationship with CytoGenix and look forward to working together to expand the market for high quality DNA." Plasmid DNA is commonly used to make many copies of a particular gene. These genes are used by researchers to test DNA-based treatments for a wide range of diseases. Traditionally, plasmid DNA is manufactured via a complex process that involves processing bacteria to yield high-grade amounts of plasmid DNA. CytoGenix' product is produced synthetically and no bacteria are required, thereby speeding the production time and increasing the purity and quality of the DNA.
Dr. Malcolm Skolnick, President and CEO commented, "This is a major milestone for CytoGenix. While our primary goal is to develop our own products, we are pleased to service the growing need for high purity cost-effective DNA. We are very excited about our relationship with Aldevron and the opportunity to supply their needs for synDNA™".
About CytoGenix: CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA _expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued US patent and over 48 international or US pending patent applications claiming methods and materials in connection with this platform technology.
SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.
Contact: CytoGenix, Inc., Kurt Berens, 713-789-0070.
Holy one when it comes down to it everyone has to make a decision. If the front office management is doing that poorly
what is it that keeps the back office R&D hanging around?
The coffee?
Why is it they do not take management to task if management is doing so poorly?
I do not believe management is not doing so poorly as some may have you think. They (management) has made some end roads. Who knows what role Aldevron is playing in this whole thing too.
They obviously have a vested interest. Why else would Aldevron put themselves down as a contact for synDNA.
CYGX will have its ups and downs. Although we never thought the SP would retreat to these levels again it has. Just goes to show how volatile the swings can be in a speculative like Cytogenix.
Remember MCET when the "real" Thaliomiles touted it saying CYGX management had not impressed him?
MULTICELL TECHS INC (OTC BB:MCET.OB) Delayed quote data
Last Trade: 0.35
Trade Time: 3:21PM ET
Change: 0.01 (2.94%)
Imagine how MCET shareholders feel.
J
On another note VOLUME. So far we have had two instances
of over 250K. One was an 800K day.
Yes I know barchart and stockta say the same things. Right after the GE PR they were bullish short intermediate and long term. Now they are bearish. One should look toward the bigger picture rather than rely on these indicators. Wind direction changes along with everything else. These indicators are no different.
When the bears are out good time to collect honey if you believe the honey to be out there.
If you believe CYGX has the goods hang in there.
If you do not believe they have much of anything just find another.
It really is that simple.
JJM LTD